‘Very Impressive’ Survival With Combo in First-Line Prostate Cancer Study

By:
On:
In: Health & Fitness

— Median overall survival with olaparib plus abiraterone reached 68 months in mid-stage trial February 27, 2026 • 3 min read SAN FRANCISCO — The first-line combination of olaparib (Lynparza) plus abiraterone (Zytiga) led to a significant overall survival (OS) advantage for patients with metastatic castration-resistant prostate cancer (mCRPC) harboringContinue Reading